These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38073685)

  • 1. Multiple therapies relieve long-term tardive dyskinesia in a patient with chronic schizophrenia: A case report.
    Lv L; Guo P; Feng M; Fang Y; Wang SK; Chen HX
    World J Clin Cases; 2023 Nov; 11(32):7895-7899. PubMed ID: 38073685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report.
    Wietholter JP; Sizemore J; Piechowski K
    Am J Health Syst Pharm; 2020 Sep; 77(18):1477-1481. PubMed ID: 32761113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.
    Soares-Weiser K; Rathbone J; Ogawa Y; Shinohara K; Bergman H
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD000208. PubMed ID: 29552749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.
    Peritogiannis V; Tsouli S
    J Psychopharmacol; 2010 Jul; 24(7):1121-5. PubMed ID: 19395427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Tardive Dyskinesia.
    Bashir HH; Jankovic J
    Neurol Clin; 2020 May; 38(2):379-396. PubMed ID: 32279716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine Treatment of Olanzapine-induced Tardive Dyskinesia: A Case Report.
    Sangroula D; Virk I; Mohammad W; Kahn DA
    J Psychiatr Pract; 2017 Jan; 23(1):53-59. PubMed ID: 28072646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report.
    Sacchetti E; Valsecchi P
    Int Clin Psychopharmacol; 2003 Nov; 18(6):357-9. PubMed ID: 14571157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia.
    Ganz ML; Chavan A; Dhanda R; Serbin M; Yonan C
    J Med Econ; 2021; 24(1):103-113. PubMed ID: 33393412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
    Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R; Annable L
    Can J Psychiatry; 2005 Oct; 50(11):703-14. PubMed ID: 16363464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management.
    Ward KM; Citrome L
    Neurol Ther; 2018 Dec; 7(2):233-248. PubMed ID: 30027457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
    El-Sayeh HG; Rathbone J; Soares-Weiser K; Bergman H
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD000458. PubMed ID: 29342497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Recommendations for Tardive Dyskinesia.
    Ricciardi L; Pringsheim T; Barnes TRE; Martino D; Gardner D; Remington G; Addington D; Morgante F; Poole N; Carson A; Edwards M
    Can J Psychiatry; 2019 Jun; 64(6):388-399. PubMed ID: 30791698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
    Frank S; Anderson KE; Fernandez HH; Hauser RA; Claassen DO; Stamler D; Factor SA; Jimenez-Shahed J; Barkay H; Wilhelm A; Alexander JK; Chaijale N; Barash S; Savola JM; Gordon MF; Chen M
    Neurol Ther; 2024 Jun; 13(3):655-675. PubMed ID: 38557959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valbenazine and Deutetrabenazine for Tardive Dyskinesia.
    Touma KTB; Scarff JR
    Innov Clin Neurosci; 2018 Jun; 15(5-6):13-16. PubMed ID: 30013814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral-paliperidone-induced tardive dyskinesia: a case report.
    Wei HT; Lai YW; Chen MH; Chen YS
    Gen Hosp Psychiatry; 2012; 34(5):578.e5-6. PubMed ID: 22154659
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.